Compare Consolidated Edison, Inc. (ED) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Consolidated Edison, Inc. trades at $111.94 (market cap $40.65B), while Recursion Pharmaceuticals Inc trades at $3.05 (market cap $1.75B). The key difference: Consolidated Edison, Inc. is far larger — about 23.2× Recursion Pharmaceuticals Inc's market cap, and Consolidated Edison, Inc. pays a 3.15% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ED | RXRX | |
|---|---|---|
Market Cap | $40.65B | $1.75B |
Sector | Utilities | Health |
52-Week High | $115.46 | $6.79 |
52-Week Low | $95.37 | $2.84 |
Enterprise Value | $67.68B | $1.17B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $111.58, down 0.32% on the day, with a bullish technical signal and strong fundamental performance. The utility company reported Q3 and Q4 2025 earnings beats but missed Q1 2026 estimates, with Q2 2026 results due August 6. ED maintains solid profitability with 12.52% net income margin and $2.02B net income in 2025, supported by $4.8B operating cash flow. Recent news highlights grid upgrades for AI data center demand and electric school bus fleet expansion.
ED offers stable dividend income with a 3.3% yield and 52-year growth streak, but faces mixed analyst sentiment (62.96% hold rating) and consensus price target of $103.50 below current price. Key risks include rising interest expenses ($1.23B in 2025) and capital-intensive grid modernization. The stock presents value for income investors despite near-term execution challenges.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
